EMA's CHMP has recommended AstraZeneca's Tagrisso for approval in the European Union to treat individuals with NSCLC.
AstraZeneca’s Tagrisso (osimertinib) has been recommended for approval in the European Union (EU) for the treatment of adult patients with locally advanced, unresectable non-small cell lung cancer ...
Panelist discusses how the second interim overall survival data from MARIPOSA-2, presented at the European Society for ...
In a move aimed at providing relief to cancer patients, the National Pharmaceutical Pricing Authority (NPPA) has directed ...
Get detailed information on Osimertinib, including pronunciation, uses, dosage guidelines, indications, and instructions on how and when to take it and when to avoid it. The updated prescription ...
News Medical on MSN4d
Scientists map cancer mutations in EGFR gene, revealing drug resistance pathsResearchers used base and prime editing to uncover new EGFR gene mutations that affect cancer progression and drug resistance ...
You should read both the consultation document and the accompanying evidence (see the committee papers) before making any comments. You must make your comments ...
ENRICHED CTCS AND CTDNA PROVIDES COMPLEMENTARY INFORMATION IN NSCLC PATIENTS TREATED WITH ASTRAZENECA'S OSIMERTINIB. The additi ...
A woman who has never smoked says she was shocked to be told she had terminal lung cancer despite being “fit and healthy”.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback